Aug. 7, 2024
The Advanced Research Projects Agency for Health (ARPA-H) within the U.S. Department of Health and Human Services recently announced the Groundbreaking Lymphatic Interventions and Drug Exploration (GLIDE) program. GLIDE aims to develop physical, pharmacologic, gene and cell-based therapeutic interventions to treat primary and rare lymphatic disease (LD) and chronic conditions complicated by lymphatic dysfunction.

GLIDE’s goals are spread across two technical areas for developing new physical and pharmacological therapies targeting abnormal lymphatic structure and function. Through advances in biomaterials, interventional radiology (IR) and minimally invasive surgical approaches and imaging, GLIDE will accelerate therapeutic options in compression, IR, microsurgery, and other minimally invasive technologies. Additionally, GLIDE will support the development of targeted pharmacologic gene and cell therapies that directly target mechanisms of lymphatic dysfunction to modulate tissue contractility and vessel growth.

For more information on the GLIDE program, ARPA-H will host a Hybrid Proposers' Day Sept. 17.

For more information about American College of Radiology® (ACR®) collaborations with ARPA-H, contact Katie Grady, ACR Government Affairs Director.

Related ACR News

  • State Legislative Bills Report

    As most state legislatures end their 2025 sessions and look to 2026, ACR staff is looking at how some radiology-specific bills they tracked fared this year.

    Read more
  • Medicare Payment Increase in Final Budget Reconciliation Bill

    The bill includes a 2.5% increase to the Medicare Physician Fee Schedule for calendar year 2026.

    Read more
  • CMS Announces Prior Authorization Test Model

    WiSer is a six-year program that will begin in six states on January 1, 2026. It will introduce prior authorization using AI technology for a select number of services, including some IR procedures.

    Read more